Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SpikoGen Booster in Kidney Transplant Recipients
NCT05285384Completed
- Sponsor
- CinnaGen
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of SpikoGen in coronavirus disease 2019 (COVID-19), sponsored by CinnaGen. Primary endpoints: Percentage of participants with seroconversion for S1 binding IgG antibodies at 1 month and Percentage of participants with seroconversion for SARS-CoV-2 neutralizing antibodies at 1 month. Started Feb 2022; status: completed.
02
Drugs
SpikoGen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05285384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285384.